CJC-1295 DAC Certificate of Analysis (COA) Standards
Evaluating a CJC-1295 DAC COA is an essential prerequisite for verifying chemical identity, sequence integrity, and purity prior to initiating preclinical protocols. As a long-acting growth-hormone-releasing hormone analog, CJC-1295 DAC requires rigorous analytical verification—including HPLC, mass spectrometry, and endotoxin testing—to ensure experimental reproducibility in laboratory settings. PX1 Research provides lot-specific analytical documentation to support high-precision cell culture and animal model studies.
Quick answer
Evaluating a CJC-1295 DAC COA is an essential prerequisite for verifying chemical identity, sequence integrity, and purity prior to initiating preclinical protocols. As a long-acting growth-hormone-releasing hormone analog, CJC-1295 DAC requires rigorous analytical verification—including HPLC, mass spectrometry, and endotoxin testing—to ensure experimental reproducibility in laboratory settings. PX1 Research provides lot-specific analytical documentation to support high-precision cell culture and animal model studies.
Key takeaways
- In modern biochemical research, the integrity of synthetic peptides directly dictates the reliability of experimental outcomes.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) with Drug Affinity Complex (DAC) is a modified 29-amino-acid peptide analog of human growth-hormone-releasing hormone (GHRH).
- A robust COA provided by an independent [ISO 17025 accredited laboratory](/research-peptides/peptide-purity-testing-guide) must explicitly detail multiple testing parameters rather than relying on generalized quality statements.
- High-Performance Liquid Chromatography (HPLC) is the gold-standard analytical technique for establishing peptide purity.
Analytical Rigor in Preclinical Peptide Sourcing
In modern biochemical research, the integrity of synthetic peptides directly dictates the reliability of experimental outcomes. When evaluating growth-hormone-releasing hormone (GHRH) analogs for laboratory research use only, principal investigators and procurement agents must verify that every lot conforms to strict chemical standards. A valid Certificate of Analysis (COA) serves as the primary document of quality assurance, proving that a compound has undergone objective, quantitative testing prior to distribution.
Obtaining a comprehensive cjc-1295 dac coa protects research models from confounding variables such as truncated peptide fragments, residual synthesis reagents, heavymetals, or bacterial endotoxins. Because CJC-1295 DAC incorporates a specific bioconjugation motif designed to extend its half-life, ensuring the full integrity of both the peptide chain and the reactive complex is essential before introducing the reagent to target assays or animal models.
Molecular Profile and Mechanism of CJC-1295 with DAC
CJC-1295 with Drug Affinity Complex (DAC) is a modified 29-amino-acid peptide analog of human growth-hormone-releasing hormone (GHRH). In preclinical models, GHRH analogs bind to the GHRH receptor on pituitary somatotropes, triggering intracellular cyclic AMP (cAMP) cascades that stimulate the synthesis and pulsatile release of endogenous growth hormone (GH). Downstream, elevated GH drives the hepatic synthesis of insulin-like growth factor 1 (IGF-1), making this pathway a fundamental area of inquiry in tissue repair research, cellular regeneration, and metabolic signaling.
The defining modification of CJC-1295 DAC is the addition of a maleimidopropionic acid linker covalently bound to the lysine residue at position 30. In vivo preclinical studies demonstrate that this reactive moiety enables the peptide to undergo spontaneous covalent conjugation with circulating serum albumin. By forming a stable albumin adduct, the complex resists rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-IV) and renal clearance. This mechanism sustains GH and downstream IGF-1 levels far longer than native GHRH or non-conjugated analogs, providing extended pharmacodynamics for longitudinal lab research.
Anatomy of an ISO 17025 Verified CJC-1295 DAC COA
A robust COA provided by an independent ISO 17025 accredited laboratory must explicitly detail multiple testing parameters rather than relying on generalized quality statements. Researchers evaluating a CJC-1295 DAC lot should verify five foundational parameters: chemical identity via high-resolution spectroscopy, chromatographic purity, endotoxin quantification, net peptide content, and physical characteristics.
Every documentation package published by PX1 Research reflects batch-specific analysis performed in domestic, GMP-compliant testing environments. Transparent reporting ensures that laboratory investigators can cross-reference batch numbers on physical vials directly with analytical reports hosted in our research library hub, validating the exact molecular characteristics of the material before unsealing.
High-Performance Liquid Chromatography (HPLC) Purity Profiling
High-Performance Liquid Chromatography (HPLC) is the gold-standard analytical technique for establishing peptide purity. During reverse-phase HPLC analysis, a sample of CJC-1295 DAC is passed through a hydrophobic stationary phase column under high pressure, separated based on affinity using a polar mobile phase gradient. As components elute from the column, an ultraviolet (UV) detector measures absorbance, generating a chromatogram with discrete peaks corresponding to the target molecule and any present impurities.
A legitimate cjc-1295 dac coa will report purity as a relative peak area percentage. The target peak for CJC-1295 DAC must represent at least 98.0% of the total integrated peak area. Minor secondary peaks represent synthesis artifacts, such as truncated sequences, deletion peptides, or oxidized species. Quantifying these impurities ensures that observed biological responses in cellular assays or tissue cultures are attributable solely to the target GHRH analog rather than background peptide fragments.
Mass Spectrometry (MS) for Molecular Mass and Sequence Confirmation
While HPLC determines purity, it cannot independently confirm chemical identity. Mass Spectrometry (MS)—typically utilizing Electrospray Ionization (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF)—is required to confirm that the synthesized sequence matches the theoretical molecular weight of CJC-1295 DAC.
The theoretical monoisotopic mass of CJC-1295 DAC is approximately 3,647.28 Daltons. The MS section of a verified COA displays mass-to-charge ratio (m/z) spectra, depicting singly and multiply charged species corresponding to the target structure. The observed mass must match the theoretical molecular weight within a strict tolerance window (typically ±1 Da). This test explicitly confirms that the Drug Affinity Complex moiety is successfully conjugated to the peptide chain, distinguishing CJC-1295 DAC from unfunctionalized peptide intermediates.
Endotoxin Testing and Bioburden Control in Preclinical Research
Endotoxins, primarily lipopolysaccharides (LPS) derived from the outer cell wall of Gram-negative bacteria, represent a severe threat to in vitro and in vivo experiment validity. Even minute concentrations of endotoxins can activate Toll-like receptor 4 (TLR4) on immune cells, triggering non-specific inflammatory cytokine release, altered cell viability, and altered gene expression that skew metabolic and tissue repair data.
PX1 Research subjects all CJC-1295 DAC lots to quantitative Limulus Amebocyte Lysate (LAL) testing or recombinant Factor C assays to establish endotoxin levels. Research-grade compounds should maintain an endotoxin threshold below 10 EU/mg (and often <1.0 EU/mg for sensitive cell cultures). Verifying strict endotoxin limits on the COA protects animal models from systemic inflammatory reactions and prevents artifactual data in delicate cellular assays.
Moisture Content, Net Peptide Content, and Physical Characterization
Lyophilized peptide preparations naturally retain residual moisture and counter-ions (such as trifluoroacetate or acetate) resulting from the purification and freeze-drying process. A complete analytical report distinguishes between total cake mass, net peptide content, and moisture percentage.
Physical inspection metrics detailed on a COA include appearance (which should uniformly present as a white to off-white, homogeneous lyophilized powder) and solubility testing. Karl Fischer titration or thermogravimetric analysis quantifies moisture, which should ideally remain below 5.0%. Knowing the exact net peptide content allows researchers to prepare precisely calibrated molar concentrations during reconstitution, preventing inadvertent under-dosing or over-dosing during in vitro experiments.
Comparative Analysis: CJC-1295 DAC vs. Related Secretagogues
When designing protocols investigating the somatotropic axis, researchers frequently compare CJC-1295 DAC against non-conjugated GHRH analogs and growth hormone secretagogues. Understanding the structural and analytical distinctions between these compounds is vital for proper reagent selection.
In contrast to CJC-1295 DAC, which features a multi-day biological half-life via albumin binding, CJC-1295 No DAC (often designated as modified GRF 1-29) lacks the reactive maleimide linker, resulting in rapid clearance typical of physiological signaling. Similarly, truncated short-chain analogs like Sermorelin retain the core 29-amino-acid active sequence of native GHRH but require frequent administration in preclinical models due to rapid enzymatic degradation. Higher molecular weight options, such as Tesamorelin, incorporate a hexenoyl group attached to the N-terminus to enhance stability against DPP-IV. Analytical COAs across these growth hormone secretagogues reflect distinct molecular masses and retention times, requiring specific HPLC methods for precise lot verification.
Red Flags and Discrepancies in Vendor COA Documentation
Procurement managers must remain vigilant against fraudulent or inadequate supplier documentation. Common red flags in the research peptide market include static, generic COAs that lack lot-specific batch numbers, missing HPLC chromatograms, or reports generated solely by in-house manufacturing teams without third-party laboratory verification.
Furthermore, a COA that omits mass spectrometry data cannot guarantee that the synthesized compound possesses the correct sequence or structural attachments. Discrepancies between the stated molecular weight and the actual spectral peak indicate contamination, structural degradation, or incorrect synthesis. PX1 Research mitigates these risks by providing independent, third-party HPLC/MS and endotoxin certification for every individual lot synthesized in USA-based facilities.
Reconstitution, Laboratory Handling, and Storage Protocols
To maintain the structural integrity confirmed on the COA, researchers must handle CJC-1295 DAC under controlled conditions upon receipt. Lyophilized vials should be stored at -20°C or -80°C for long-term stability, protected from light and atmospheric moisture exposure.
Reconstitution for laboratory research use should be performed inside a certified laminar flow hood using sterile, bacteriostatic or deionized water. Avoid vigorous vortexing, as shear forces can disrupt peptide tertiary structure or cause aggregation. Once reconstituted, liquid aliquots should be stored at 4°C for short-term assays or frozen at -80°C to prevent degradation over extended experimental timelines. Institutional clients purchasing bulk quantities through PX1 wholesale accounts receive standardized handling documentation alongside complete analytical packages.
Frequently Asked Questions
What core testing methods must a valid CJC-1295 DAC COA contain?
A valid CJC-1295 DAC COA must include reverse-phase High-Performance Liquid Chromatography (HPLC) for purity quantification, Mass Spectrometry (ESI-MS or MALDI-TOF) for molecular mass confirmation, Limulus Amebocyte Lysate (LAL) testing for endotoxin levels, and physical testing for lyophilized appearance and moisture content.
How does the Drug Affinity Complex (DAC) alter the mass spectrometry profile?
The addition of the Drug Affinity Complex (a maleimidopropionic acid linker) adds a specific mass increment to the peptide backbone. The theoretical mass shifts from approximately 3,367 Da (non-DAC modified GRF 1-29) to roughly 3,647 Da. Mass spectrometry confirms that the reactive linker is covalently bound to the lysine residue.
What is the baseline HPLC purity threshold for research-grade CJC-1295 DAC?
Research-grade CJC-1295 DAC supplied by PX1 Research maintains an HPLC purity threshold of ≥98.0%. High purity ensures that experimental results in cell lines or animal models are free from confounding background effects caused by synthesis fragments or truncated sequences.
Why is endotoxin quantitation essential for CJC-1295 DAC research?
Endotoxins cause non-specific inflammatory responses via TLR4 receptor pathways in living tissues and cell cultures. Quantitative endotoxin testing ensures levels remain well below toxic thresholds (<10 EU/mg), preventing artifactual immune activation in preclinical protocols.
How should CJC-1295 DAC be stored upon delivery to the laboratory?
Lyophilized CJC-1295 DAC should be stored in a freezer at -20°C or -80°C upon receipt. Reconstituted solutions should be stored at 4°C for immediate short-term use or aliquoted and frozen at -80°C to avoid repeated freeze-thaw cycles.
How does CJC-1295 DAC differ analytically from CJC-1295 No DAC?
Analytically, CJC-1295 DAC possesses a higher molecular weight (3,647 Da vs 3,367 Da) and a distinct retention time on reverse-phase HPLC due to the altered hydrophobic interactions introduced by the maleimide linker.
What is the acceptable moisture level listed on a peptide COA?
Acceptable moisture levels in high-quality lyophilized peptides typically fall below 5.0%. Excess residual moisture can accelerate peptide degradation via hydrolysis during storage.
Does PX1 Research provide lot-specific COAs for institutional purchases?
Yes. PX1 Research provides downloadable, lot-specific COAs verified by independent ISO 17025 accredited laboratories for every batch of research peptides distributed to qualified institutions.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.